Lantern Pharma Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 87/100
What the filing says
On September 25, 2026, Lantern Pharma Inc. received notice from its exchange of failure to satisfy continued listing standards, triggering a Form 8-K filing on October 1, 2026. The filing provides no specific details regarding which listing rule was violated, remediation timeline, or the company's response plan. Given the company's $33.9M market cap, delisting would materially impair equity access and liquidity.
Why this rating
Delisting notice is business-threatening for sub-$50M cap; triggers existential exchange/funding risk and severe equity deterioration risk.
Extracted items
Price action (we called it negative)
before filing · preread $1.00 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.